- Home
- KPTI vs DHAI Comparison
KPTI vs DHAI Comparison
Compare KPTI & DHAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- DHAI
- Stock Information
- Founded
- KPTI 2008
- DHAI 2007
- Country
- KPTI United States
- DHAI United States
- Employees
- KPTI N/A
- DHAI N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- DHAI
- Sector
- KPTI Health Care
- DHAI
- Exchange
- KPTI Nasdaq
- DHAI NYSE
- Market Cap
- KPTI 44.5M
- DHAI 49.1M
- IPO Year
- KPTI 2013
- DHAI N/A
- Fundamental
- Price
- KPTI $4.20
- DHAI $0.23
- Analyst Decision
- KPTI Buy
- DHAI
- Analyst Count
- KPTI 6
- DHAI 0
- Target Price
- KPTI $48.50
- DHAI N/A
- AVG Volume (30 Days)
- KPTI 86.5K
- DHAI 1.2M
- Earning Date
- KPTI 05-12-2025
- DHAI 07-14-2025
- Dividend Yield
- KPTI N/A
- DHAI N/A
- EPS Growth
- KPTI N/A
- DHAI N/A
- EPS
- KPTI N/A
- DHAI N/A
- Revenue
- KPTI $142,126,000.00
- DHAI $69,573,000.00
- Revenue This Year
- KPTI $2.34
- DHAI N/A
- Revenue Next Year
- KPTI $13.81
- DHAI N/A
- P/E Ratio
- KPTI N/A
- DHAI N/A
- Revenue Growth
- KPTI 1.19
- DHAI 5.40
- 52 Week Low
- KPTI $3.51
- DHAI $0.12
- 52 Week High
- KPTI $17.40
- DHAI $3.67
- Technical
- Relative Strength Index (RSI)
- KPTI 35.16
- DHAI 52.62
- Support Level
- KPTI $4.33
- DHAI $0.21
- Resistance Level
- KPTI $4.65
- DHAI $0.28
- Average True Range (ATR)
- KPTI 0.47
- DHAI 0.03
- MACD
- KPTI -0.12
- DHAI 0.00
- Stochastic Oscillator
- KPTI 8.95
- DHAI 57.14
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About DHAI DIH HOLDINGS US INC
DIH Holding US Inc is a provider of robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions. Its products Armeo Power, Armeo Spring, Armeo Spring Pro, etc.